Level of Evidence (LOE) Added to Clinical Pharmacology

Clinical Pharmacology, as part of compliance with requirements as a CMS compendium for Oncology Off-Label Use, is now providing additional transparency and information regarding the off-label indications for oncology drugs. Utilizing established evidence-based medicine techniques following the GRADE system., Clinical Pharmacology now provides additional Level of Evidence data that provides background regarding the studies evaluated in regards to the drug’s off-label use.

• Included as part of the indication data provided in Clinical Pharmacology, users will find:
• Each off-label use assigned a quality of evidence rating and a strength of recommendation.
• Recommended/Not Recommended clearly indicated
• Two strengths of recommendation: Strong and Equivocal/Weak
• Four (4) quality of evidence levels
• High
• Moderate
• Low
• Very Low
• Evidence Summary Table
• Quick summary of key studies reviewed for the indication
• Allows for comparison of dosing, patient populations, outcomes and evidence ratings
• Discussion Section summarizing evidence and recommendations
• References including summary and any additional references

The above structure was created to support all off-label uses and will expand to additional therapeutic uses.

For more information about Clinical Pharmacology, please visit the product page at goldstandard.com. For account service or technical support, please contact us at (800) 375-0943 Ext. 1 or support@goldstandard.com.